GlassScriptPhysician profile
Peter S Masny
NPI 1144376740
$2,736.94
in general payments reported to CMS, 2019-2025
29 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $156 · 2021: $23.91 · 2022: $128 · 2023: $34.15 · 2024: $40.21 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.56 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.35 | 2019-2025 | |
| Biogen, INC. | $198.07 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $191.40 | 2019 | |
| Ucb, INC. | $173.03 | 2019-2025 | Rystiggo |
| Lilly USA, LLC | $154.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $151.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $137.41 | 2019 | |
| Allergan, INC. | $134.03 | 2019-2021 | |
| Amgen INC. | $123.88 | 2019 | |
| Greenwich Biosciences, INC. | $115.87 | 2019 | |
| Neurocrine Biosciences, INC. | $110.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $108.37 | 2019 | |
| Amneal Pharmaceuticals LLC | $99.86 | 2019 | |
| Abbott Laboratories | $87.34 | 2022-2025 | Infinity |
| Csl Behring | $74.91 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $70.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $66.49 | 2019 | |
| Adamas Pharmaceuticals, INC. | $66.25 | 2019 | |
| Acorda Therapeutics, INC | $60.71 | 2019 | |
| Mdd US Operations, LLC | $60.28 | 2019 | |
| Genentech USA, INC. | $36.35 | 2019 | |
| Kyowa Kirin, INC. | $24.89 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.80 | 2019 | |
| Genzyme Corporation | $24.06 | 2019 | |
| Medtronic, INC. | $23.04 | 2022 | |
| Boston Scientific Corporation | $22.11 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.12 | 2019 | |
| Grifols USA, LLC | $16.48 | 2019 | |
| Horizon Therapeutics Plc | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Masny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.